ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1883

Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission

Pablo Vinicius da Fonseca, Henrique Ayres Mayrink Giardini,, Célio Roberto Gonçalves and Leandro Lara do Prado, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Meeting: ACR Convergence 2021

Keywords: Behçet's Syndrome, neurology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Behçet’s disease (BD) is a systemic vasculitis. Neurological involvement, also known as Neuro-Behçet’s disease (NBD), leads to great morbimortality. Diagnosis is challenging, since clinical presentation fluctuate greatly and systemic findings may be scarce, even after 2014 Classification Criteria included neurological manifestations. Treatment is based on corticosteroids and immunosuppressants, with azathioprine being widely used and tumor necrosis factor inhibitors (TNFi) as an option in refractory cases. Since access to TNFi is difficult, cyclophosphamide (CYC) may be used in severe NBD cases. However, strong evidence to corroborate its indications and treatment regimens are lacking. Our objective isto describe NBD patients’ features, as well as safety and efficacy data of twenty years’ experience of CYC use at a tertiary rheumatology center.

Methods: Retrospective cohort with data collected from electronic medical record, from January 2000 to December 2020, using keywords determinants. Treatment regimens allowed were methylprednisolone 1g for 3 to 5 days, followed by CYC 0.5 – 1g/m2 monthly for at least three months and compared to other immunosuppressant regimens (azathioprine, mycophenolate, TNFi). Subjects were divided in CYC and non-CYC groups and chi-square was used for statistical analysis.

Results: Fifty-nine patients were included, 27 in the non-CYC group (55,55% women) and 32 in the CYC group (56,25% women). Mean age at BD diagnosis was 32.48 years in the non-CYC group and 29.75 years in the CYC group (p >0.05). Mean time from BD diagnosis to NBD was 26.85±9 months in the non-CYC group and 22.96±9,8 months in the CYC group (p >0.05). Mean follow-up months were 139.14 ±88 months in the non-cycle group and 78.78 ±43 months in the CFF group. Relapse rate was 14.8% in non-CYC versus 37.5% in CYC group (p >0.05), however relapse rate at 12-months follow-up was 50% at non-CYC group versus 12,5% at CYC group (p >0.05). Mean time for relapse was 30.5 versus 57.9 months at non-CYC and CYC groups, respectively (p >0.05). Mean cumulative CYC dose was 12.09g with an average of 10 infusions. There were 3 serious adverse events in each group (p >0.05).

Conclusion: Lower relapse rate at 12-months follow-up was a tendency in CYC patients in addition to sustained remission for a longer time, compared to other immunosuppressants. CYC use for NBD induction of remission presented a good safety profile, with few adverse effects and acceptable mean cumulative dose. Our study could not reach statistical significance due to small sample analysis and prospective studies are necessary to confirm relapse rates and establish the best CYC therapeutic schemes.

1.jpeg”Acute stage rhomboencephalitis

2.jpeg”After three months of treatment


Disclosures: P. Fonseca, None; H. Giardini,, None; C. Gonçalves, None; L. Prado, None.

To cite this abstract in AMA style:

Fonseca P, Giardini, H, Gonçalves C, Prado L. Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/neuro-behcets-disease-20-years-single-center-experience-of-cyclophosphamide-for-induction-of-remission/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neuro-behcets-disease-20-years-single-center-experience-of-cyclophosphamide-for-induction-of-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology